ArticleESC heart failure2021
Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02916160 (Evaluation in Real Life Conditions of Sacubitril-valsartan Combination in Patients With Chronic Heart Failure and Sleep Apnea Syndrome), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation in Real Life Conditions of Sacubitril-valsartan Combination in Patients With Chronic Heart Failure and Sleep Apnea Syndrome
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Investigating the effect of valsartan/sacubitril on sleep parameters of patients with sleep apnea: systematic review and meta-analysis.Sleep & breathing = Schlaf & Atmung · 2026Pooled it
- Impact of sacubitril/valsartan on chronic heart failure patients with sleep-disordered breathing: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Pharmacological treatment for central sleep apnoea in adults.The Cochrane database of systematic reviews · 2023Pooled it
- Effects of SGLT2 Inhibitors on Sleep Apnea Parameters and Cheyne-Stokes Respiration in Patients with Acute Decompensated Heart Failure: A Prospective Cohort Study.Biomedicines · 2025Article
- Recent Insights into the Relationship Between Sleep Disordered Breathing and Cardiovascular Disease.Yonago acta medica · 2025Review
- The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Article
- Review
- Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Dapagliflozin-entresto protected kidney from renal hypertension via downregulating cell-stress signaling and upregulating SIRT1/PGC-1α/Mfn2-medicated mitochondrial homeostasis.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Association between Obstructive Sleep Apnea and Heart Failure in Adults-A Systematic Review.Journal of clinical medicine · 2023Review
- Article
- Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea.ERJ open research · 2023Article
- Sudden cardiac death prevention in the era of novel heart failure medications.American heart journal plus : cardiology research and practice · 2023Review
- Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction.Sleep & breathing = Schlaf & Atmung · 2023Article
- Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea.Frontiers in cardiovascular medicine · 2022Article
- Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOptimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation based on six studies encompassing a total of 67 patients only. Whether sacubitril-valsartan (SV), a cornerstone of HFrEF medical treatment, impacts SA is unknown and requires evaluation. METHODS AND
resultsThe ENTRESTO-SAS trial is a six-centre, prospective, open-label real-life cohort study (NCT02916160). Ambulatory patients eligible for SV (i.e. HFrEF adults who remain symptomatic despite optimal treatment) were evaluated before and after 3 months of SV (including nocturnal ventilatory polygraphy); 118 patients were final analysed [median age was 66 (IQ
conclusionsIn this real-life population, SV treatment for 3 months in SA patients is associated with a significant decrease in AHI. These results support the current guidelines that recommend first an optimization of the HFrEF treatment in patients with HFrEF and central SA. A potential positive airway pressure sparing effect merits further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.